What it sells
Cancer therapy.
Business model breakdown
Buyer: who owns the budget?
UnverifiedPotential pharma partners; patients via trials.
Economics: what it saves and how it charges
Clinical-stage biotech financed by equity ($14M Series A extension closed August 19, 2026); no revenue.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| 2026-08-19 | Series A | $25M | — | news.google.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.